SB 134 takes positive steps toward updating Kentucky law to cover biologics and biosimilars in
a way that protects patients. As you know, unlike traditional chemical drugs, biologics are
unique, complex structures made from living cells that are not easily replicated. A small change
or difference in the biosimilar or biologic manufacturing process has the potential to adversely
impact the patient.
SB 313 takes positive steps toward updating Connecticut law to cover biologics and biosimilars
in a way that protects patients.
The committee will discuss biologics license application (BLA) 125544, for CT-P13, a
proposed biosimilar to Janssen Biotech Inc.’s REMICADE (infliximab), submitted by Celltrion,
Congratulations on your confirmation by the U.S. Senate to serve as the 22nd Commissioner of the U.S. Food and Drug Administration . You join a distinguished list of public health leaders who have headed one of the federal government’s most important agencies.
The Global Healthy Living Foundation (GHLF) is a 501 (c)(3) patient group that works to
improve the quality of life for people with chronic disease, often focusing on those least able to advocate for themselves.